药品信息速递

订阅

MedSci主页 / 所有栏目 / 药品信息速递

欧盟批准AZ的Lokelma治疗高钾血症

2018-03-25 MedSci MedSci原创

Lokelma
关注

阿斯利康(AstraZeneca)的Lokelma已获准在欧洲治疗成人高钾血症。高钾血症的特征是血液中的钾含量升高。对于慢性肾脏疾病患者以及那些采用普通救命药物治疗心力衰竭的患者，如肾素-血管紧张素-醛固酮系统（RAAS）抑制剂，可增加血液中的钾含量，患病风险显著增加。该公司指出，为了帮助预防高钾血症的复发，RAAS抑制剂治疗常常被修改或中断，但这可能会危及心肾结果并增加死亡风险。Loke


阿斯利康(AstraZeneca)的Lokelma已获准在欧洲治疗成人高钾血症。


高钾血症的特征是血液中的钾含量升高。对于慢性肾脏疾病患者以及那些采用普通救命药物治疗心力衰竭的患者，如肾素-血管紧张素-醛固酮系统（RAAS）抑制剂，可增加血液中的钾含量，患病风险显著增加。


该公司指出，为了帮助预防高钾血症的复发，RAAS抑制剂治疗常常被修改或中断，但这可能会危及心肾结果并增加死亡风险。


Lokelma（以前称为ZS-9，环硅酸钠锆）是一种不溶性，未被吸收的化合物，具有优先捕获钾离子的结构。


在临床试验中，服用该药的高钾血症患者达到正常钾水平的中位时间为2.2小时，其中98%的患者在48小时内达到正常水平。


"高钾血症的后果可能是严重的，甚至是危及生命的，而且可能发生在慢性肾病患者或服用一些药物治疗心力衰竭的病人身上，"AZ的心血管、肾脏和代谢、全球药物开发主管Elisabeth Bjork说。


"Lokelma的批准"通过为高钾血症患者提供快速和持续的治疗选择来解决重大的未满足的需求。


Lokelma在美国仍在接受审查，之前因为制造问题被美国食品和药物管理局拒绝。


AZ于2015年通过收购ZS Pharma获得该药物的权利。


原文出处：http：//www.pharmatimes.com/news/eu_approves_az_potassium_binder_for_hyperkalaemia_1229022


此文系梅斯医学（MedSci)原创整理编译，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1714774, encodeId=b8331e1477440, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Mon Dec 03 11:43:00 CST 2018, time=2018-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514522, encodeId=d633151452251, content=<a href='/topic/show?id=102f102e8375' target=_blank style='color:#2F92EE;'>#高钾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102783, encryptionId=102f102e8375, topicName=高钾)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5d010658633, createdName=ms7517674339485982, createdTime=Tue Mar 27 00:43:00 CST 2018, time=2018-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589988, encodeId=3ed9158998804, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Tue Mar 27 00:43:00 CST 2018, time=2018-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250259, encodeId=1bf812502595a, content=<a href='/topic/show?id=cfe6109990e' target=_blank style='color:#2F92EE;'>#Lokelma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10999, encryptionId=cfe6109990e, topicName=Lokelma)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=杏林小小, createdTime=Sun Mar 25 12:43:00 CST 2018, time=2018-03-25, status=1, ipAttribution=)]
    2018-12-03 12498e5fm22(暂无昵称)

    #AZ#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1714774, encodeId=b8331e1477440, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Mon Dec 03 11:43:00 CST 2018, time=2018-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514522, encodeId=d633151452251, content=<a href='/topic/show?id=102f102e8375' target=_blank style='color:#2F92EE;'>#高钾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102783, encryptionId=102f102e8375, topicName=高钾)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5d010658633, createdName=ms7517674339485982, createdTime=Tue Mar 27 00:43:00 CST 2018, time=2018-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589988, encodeId=3ed9158998804, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Tue Mar 27 00:43:00 CST 2018, time=2018-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250259, encodeId=1bf812502595a, content=<a href='/topic/show?id=cfe6109990e' target=_blank style='color:#2F92EE;'>#Lokelma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10999, encryptionId=cfe6109990e, topicName=Lokelma)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=杏林小小, createdTime=Sun Mar 25 12:43:00 CST 2018, time=2018-03-25, status=1, ipAttribution=)]
    2018-03-27 ms7517674339485982

    #高钾#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1714774, encodeId=b8331e1477440, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Mon Dec 03 11:43:00 CST 2018, time=2018-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514522, encodeId=d633151452251, content=<a href='/topic/show?id=102f102e8375' target=_blank style='color:#2F92EE;'>#高钾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102783, encryptionId=102f102e8375, topicName=高钾)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5d010658633, createdName=ms7517674339485982, createdTime=Tue Mar 27 00:43:00 CST 2018, time=2018-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589988, encodeId=3ed9158998804, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Tue Mar 27 00:43:00 CST 2018, time=2018-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250259, encodeId=1bf812502595a, content=<a href='/topic/show?id=cfe6109990e' target=_blank style='color:#2F92EE;'>#Lokelma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10999, encryptionId=cfe6109990e, topicName=Lokelma)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=杏林小小, createdTime=Sun Mar 25 12:43:00 CST 2018, time=2018-03-25, status=1, ipAttribution=)]
    2018-03-27 chenwq14

    #欧盟批准#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1714774, encodeId=b8331e1477440, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Mon Dec 03 11:43:00 CST 2018, time=2018-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514522, encodeId=d633151452251, content=<a href='/topic/show?id=102f102e8375' target=_blank style='color:#2F92EE;'>#高钾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102783, encryptionId=102f102e8375, topicName=高钾)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5d010658633, createdName=ms7517674339485982, createdTime=Tue Mar 27 00:43:00 CST 2018, time=2018-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589988, encodeId=3ed9158998804, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Tue Mar 27 00:43:00 CST 2018, time=2018-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250259, encodeId=1bf812502595a, content=<a href='/topic/show?id=cfe6109990e' target=_blank style='color:#2F92EE;'>#Lokelma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10999, encryptionId=cfe6109990e, topicName=Lokelma)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=杏林小小, createdTime=Sun Mar 25 12:43:00 CST 2018, time=2018-03-25, status=1, ipAttribution=)]
    2018-03-25 杏林小小

    #Lokelma#

    0